Testing a new drug and procedure for advanced pancreatic cancer
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests a new drug called mitazalimab injected directly into the tumor, combined with a special electrical procedure that kills cancer cells. It is for people whose pancreatic cancer has not spread but cannot be removed by surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of pancreatic cancer called pancreatic ductal adenocarcinoma (PDAC) that has not spread to other parts of the body.
- Your cancer is considered locally advanced, meaning it has grown into nearby blood vessels and cannot be removed completely with surgery.
- You have received at least 4 months of standard chemotherapy (like FOLFIRINOX or gemcitabine with nab-paclitaxel).
- Your main tumor is smaller than 4 cm and can be fully treated with the electrical procedure.
- You are generally able to care for yourself (ECOG performance status 0-2).
- You have not had radiation to the pancreas or treatment with a CD40 antibody before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new immunotherapy drug called ivonescimab combined with chemotherapy, with or without another experimental drug (AK117), for people with pancreatic cancer that has spread. The goal is to see if adding these therapies can help shrink tumors or slow the cancer's growth.
This trial tests a new kind of immunotherapy for pancreatic cancer that has not been removed by surgery or has spread. It aims to see if the treatment can help shrink or control the cancer, and you may be eligible whether you have had previous chemotherapy or not.
This trial tests a new combination: a special electric field treatment (IRE) plus a dual-function antibody (PD-1/CTLA-4) for people with locally advanced pancreatic cancer that didn't respond to standard chemotherapy. The goal is to see if this approach can help shrink or control the cancer.
This trial studies a procedure called NanoKnife IRE for pancreatic cancer that cannot be removed surgically after standard chemotherapy or radiation. It uses electric pulses to destroy tumor cells and may be an option for patients who have completed other treatments.
This trial tests a new drug (OMTX705) combined with standard chemotherapy (gemcitabine/nab-paclitaxel) and an immunotherapy (tislelizumab) for people with advanced pancreatic cancer. It may be an option if you have had little or no prior chemotherapy.
This trial tests a combination of radiation, an immunotherapy drug (adebrelimab) and a chemotherapy regimen (NALIRIFOX) before any surgery, for people with locally advanced pancreatic cancer. The goal is to shrink the tumor enough to make surgery possible, potentially improving outcomes.
Hear when a new Pancreatic cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.